Serum lipids, lipoproteins and apolipoproteins A and B in epileptic patients treated with valproic acid, carbamazepine or phenobarbital

Acta Neurol Scand. 1991 Apr;83(4):250-3. doi: 10.1111/j.1600-0404.1991.tb04691.x.

Abstract

Serum lipids, lipoproteins and apolipoproteins A and B were measured in 101 epileptic patients receiving chronic treatment with valproic acid, carbamazepine or phenobarbital and in 75 age- and sex-matched control subjects. In relation to controls, subjects treated with valproic acid showed significantly lower values of total and LDL-cholesterol levels; subjects treated with carbamazepine showed significantly higher values of HDL-cholesterol and apolipoprotein A concentrations and subjects treated with phenobarbital showed significantly higher values of total cholesterol, HDL-cholesterol, apolipoprotein A and apolipoprotein B levels. The total cholesterol/HDL-cholesterol ratio was significantly lower in patients receiving valproic acid or carbamazepine but not in the phenobarbital-treated group. Changes in serum lipids profile did not correlate with drug plasma concentrations nor the duration of the treatment.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Adult
  • Analysis of Variance
  • Apolipoproteins A / blood
  • Apolipoproteins B / blood
  • Carbamazepine / therapeutic use*
  • Child
  • Child, Preschool
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood
  • Cholesterol, VLDL / blood
  • Epilepsy / blood*
  • Epilepsy / drug therapy*
  • Female
  • Humans
  • Lipids / blood*
  • Male
  • Middle Aged
  • Phenobarbital / therapeutic use*
  • Valproic Acid / therapeutic use*

Substances

  • Apolipoproteins A
  • Apolipoproteins B
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Cholesterol, VLDL
  • Lipids
  • Carbamazepine
  • Valproic Acid
  • Phenobarbital